Categories: DevelopmentDiagnosticsFastFinTechHardwareHealthTechLearn
Neosens addresses a global health concern, the unnecessary antibiotic treatment of 12% of all newborns in low- and middle-income countries (LMICs) due to sepsis suspicion.
These overtreatments lead to serious adverse effects for newborns and place a significant financial burden on those countries. They also contribute to the alarming increase in antibiotic resistance, which is seen as a global health and development threat by the WHO.
We are developing a portable diagnostic device that combines the power of Machine Learning models with biomarker concentration measurements. Our device offers a solution that is not only fast and accurate but also highly cost-effective. Our customers will be able to save thousands of dollars per year while reducing up to 2/3 of these overtreatments.
Investors 1
Mentions in press and media 3
Reviews 0
